SS-31

SS-31, also called elamipretide, is a synthetic four-amino-acid peptide that targets your mitochondria, the structures inside every cell that generate energy. As mitochondria age or get damaged, they leak energy, produce more oxidative stress, and lose their ability to make ATP efficiently. SS-31 binds to a fat called cardiolipin in the inner mitochondrial membrane and helps restore that membrane's structure, which translates into better energy output and less cellular wear.

Most people interested in SS-31 are looking at it for one of three reasons: age-related fatigue and exercise intolerance, recovery from cardiac or muscular conditions tied to mitochondrial dysfunction, or general healthspan. It's the first mitochondria-targeted drug to reach FDA approval (approved as Forzinity in September 2025 for Barth syndrome, a rare genetic mitochondrial disease), and a single 2-hour infusion in older adults restored mitochondrial ATP capacity in skeletal muscle immediately after dosing. It will not turn back the clock, and large heart failure trials have been mostly negative, so expectations should be calibrated. If you're a healthy 30-year-old with normal energy, this is not for you. If you're an older adult with fatigue, post-exertional crashes, or known mitochondrial-driven decline, this is one of the more interesting tools available.

Deep-dive

Mechanism

SS-31 (D-Arg-2'6'-dimethylTyr-Lys-Phe-NH₂) is a positively charged tetrapeptide that crosses cell membranes and concentrates 1,000-5,000x in mitochondria. Once there, it binds cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin holds the cristae, the folds where the electron transport chain lives, in their proper shape. With age, disease, or oxidative stress, cardiolipin becomes peroxidized and the cristae destabilize, which leaks protons, lowers ATP output, and increases reactive oxygen species.

SS-31 changes the surface electrostatics of the inner membrane, which protects cardiolipin from peroxidation, stabilizes the supercomplexes of the electron transport chain, and improves how efficiently mitochondria turn oxygen into ATP (the P/O ratio). It was originally framed as a mitochondrial antioxidant, but the current understanding is that it's primarily a structural and electrostatic modulator of the inner mitochondrial membrane, with antioxidant effects following downstream. Newer work also shows it improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator (ANT), which is part of why effects show up so quickly.

What the human evidence actually shows

Aging muscle. In a randomized, placebo-controlled trial in 39 adults aged 60-85 with poor mitochondrial function at baseline, a single IV infusion increased ATPmax in skeletal muscle immediately post-infusion, with the effect gone by day 7 (consistent with the drug's short half-life). Fatigue resistance did not change after one dose. This is the cleanest evidence in healthy older adults, and it shows SS-31 works rapidly but reversibly.

Barth syndrome. The basis for FDA approval. In the TAZPOWER trial and its 168-week open-label extension, patients on 40 mg daily SC improved 6-minute walk distance by roughly 96 meters cumulatively at week 168 and showed gains in muscle strength, fatigue, and cardiac stroke volume. This is a small, ultra-rare disease population, but the long-term consistency is meaningful.

Primary mitochondrial myopathy. The phase 3 MMPOWER-3 trial in 218 patients failed its primary endpoints (6-minute walk test and fatigue score) at 24 weeks. A post-hoc analysis found benefit specifically in the subgroup with nuclear DNA mutations, not mtDNA mutations. A follow-up trial (NuPOWER) is now testing this hypothesis directly.

Heart failure. The PROGRESS-HF phase 2 trial in 71 HFrEF patients showed no improvement in left ventricular end-systolic volume at 4 weeks. Earlier single-infusion work suggested dose-dependent reductions in ventricular volumes, but chronic dosing has not panned out for heart failure broadly.

Dry AMD. The phase 2 ReCLAIM-2 trial in 176 patients with non-central geographic atrophy did not hit its co-primary endpoints, though signals on ellipsoid zone integrity were noted.

The honest summary: SS-31 reliably improves mitochondrial bioenergetics on biomarker and imaging endpoints, but translating that into hard clinical outcomes has been hit or miss. The strongest evidence sits in (a) acute mitochondrial energetics in aging muscle and (b) Barth syndrome.

For women

Women have generally been underrepresented in mitochondrial drug research, but SS-31 has reasonable female-specific data. MMPOWER-3 was 64% women, and older women appear to respond at least as well as men, possibly better in some tissues. In a 2025 mouse aging study published in Aging Cell, aged female mice showed steeper declines in skeletal muscle force than males, and 8 weeks of elamipretide partially reversed this decline specifically in females. This is notable because most longevity drugs (rapamycin, metformin) tend to extend healthspan more in male mice than female mice. SS-31 may be one of the rare interventions that translates evenly, or even favors women, in muscle aging.

Mitochondrial biology also intersects with oestrogen, which independently supports mitochondrial biogenesis and antioxidant defense. After menopause, mitochondrial efficiency drops faster, and that's a plausible window where SS-31 may be most useful for women, though no trial has tested this directly.

For older adults

The aging-muscle data is the strongest case. Renal function declines with age, and SS-31 is renally cleared, so older adults with reduced eGFR need dose reduction (see Dosing). The effect is short-lived, so chronic dosing matters more than one-off use.

Limitations of the evidence

SS-31 has had high-profile clinical failures (heart failure, mitochondrial myopathy as a whole population, dry AMD). Most of the strongest data is in mouse models or in small, selected human cohorts. Long-term human safety beyond ~3 years is documented mainly in Barth syndrome patients on daily dosing. There is essentially no data in healthy young adults using it for performance or longevity, despite that being the dominant off-label use case. Most positive aging data uses IV or subcutaneous routes; oral SS-31 has limited published evidence for systemic effect.

Dosage:

Practical healthspan dose: 5-10 mg subcutaneous, once daily. This aligns with the Conley aging-muscle trial which used roughly 0.10 mg/kg IV (about 7 mg for a 70 kg adult) and showed restored ATP capacity in older adults with poor mitochondrial function. There's no human evidence that going higher adds benefit outside of disease states

Disease-state dose: 40 mg subcutaneous daily. This is the FDA-approved Forzinity dose for Barth syndrome and the dose used in most phase 2 and 3 trials. Worth considering if you're using SS-31 to address an actual mitochondrial pathology rather than for general support

Lower starting doses (4 mg daily) were tested in the PROGRESS-HF heart failure trial alongside 40 mg, with similar tolerability between the two. Reasonable starting point for sensitive users

Bioavailability is around 92% subcutaneously; thigh and abdomen give comparable exposure. Rotate sites to reduce skin reactions

Half-life is roughly 3-4 hours, so once-daily dosing produces an acute peak rather than steady state. Some users split into twice-daily for sustained tissue exposure, though this is not validated in trials

Cycling: not formally studied. Many users run 4-8 week cycles followed by a break. Continuous use up to 168 weeks has been documented as safe in Barth syndrome at the 40 mg dose

Reduce dose by half if eGFR is below 30 mL/min (so 20 mg if you'd otherwise be on 40, 2.5-5 mg if you'd otherwise be on 5-10). Not studied in dialysis. No adjustment needed for liver impairment as it has no hepatic metabolism

Older adults clear the metabolites M1 and M2 more slowly, so starting at the low end and titrating up is sensible

Women have not shown a need for sex-based dose adjustment in trials

Storage: refrigerated at 2-8°C. Don't freeze. Don't shake hard, which damages the peptide

Timing: inject at the same time daily for consistency. If you miss a dose, skip it; don't double up

Here's what you can expect:

For most users, the noticeable effect is on energy, exercise tolerance, and muscle fatigue. It tends to show up within days, not weeks, because the mechanism is acute restoration of mitochondrial function rather than slow remodeling. Some people describe it as cleaner endurance with less perceived effort during cardio. Others notice better recovery between training sessions or reduced post-viral or post-exertional fatigue.

What you should not expect: dramatic strength or muscle size changes, fat loss, or noticeable cognitive enhancement. SS-31 is not a stimulant. If you have normal mitochondrial function to begin with, the effect is likely subtle or imperceptible. The older adult trial specifically enrolled people with poor mitochondrial function, and even there fatigue resistance did not change after a single dose.

The effect washes out within days of stopping. There is no carryover benefit unless you redose.

Side effects & risks:

Injection site reactions are by far the most common. Redness, mild pain, itching, occasional bruising or induration. In the TAZPOWER Barth syndrome trial, 100% of treated patients had at least one of these, though almost all were mild. Rotating injection sites helps

Headache and dizziness occur in roughly 10-30% of users in trials

Mild GI discomfort (nausea, fatigue) has been reported and was the cause of one discontinuation in the heart failure trial

Hypersensitivity reactions have occurred in a small minority on the FDA-approved product and require stopping use

No serious treatment-related adverse events have been linked to SS-31 in any published trial, including in patients on daily dosing for over 3 years. There's no established risk of cancer, organ damage, or hormone disruption from the published data, but trials in healthy adults are short and most chronic-use data comes from a small Barth syndrome population

Drug interactions appear minimal. SS-31 doesn't go through CYP enzymes and doesn't inhibit common transporters. It's renally cleared, so anything that significantly impairs kidney function will increase exposure

Pregnancy and breastfeeding: not studied. Avoid if pregnant, trying to conceive, or breastfeeding

🩸

Blood markers

Comprehensive metabolic panel including eGFR and creatinine — baseline before starting, because dose depends on kidney function. Recheck at 8-12 weeks if using chronically, especially over 60.

Lactate — the most commonly used screening marker for mitochondrial dysfunction. Elevated levels suggest impaired pyruvate handling. Useful baseline if you have unexplained fatigue or post-exertional symptoms. Anyone elevated at baseline is a more likely responder and worth retesting.

GDF-15 and FGF-21 — the most validated blood biomarkers of mitochondrial dysfunction, with GDF-15 having the best diagnostic performance. Worth checking at baseline if available, especially if you suspect mitochondrial-driven symptoms.

Creatine kinase (CK) — baseline if you have muscle symptoms, recheck at 8-12 weeks alongside eGFR.

NT-proBNP — only relevant if you're using SS-31 for a cardiac indication.

Healthy adults running short cycles can reasonably skip routine bloodwork as long as baseline kidney function is normal. The people who actually need labs are anyone with reduced eGFR, anyone with a known cardiac or muscular condition, and anyone over 60 using it chronically.

Sold as a research chemical. Approved as Forzinity (elamipretide HCl) for Barth syndrome only.